ABBV vs ABT
AbbVie Inc. (ABBV) and Abbott Laboratories (ABT) are both filed with the SEC under Pharmaceutical Preparations. ABBV is 2.3× ABT's size by market cap ($456.2B against $194.4B); ABBV trades at the higher fiscal-year P/E (109.4× against 30.0×); ABT reports the higher net margin (14.7% against 6.9%); ABBV grew sales faster over three years (+1.8% against +0.5%); and over the past year ABBV returned +25.8% against ABT's -13.0%.
| ABBV | ABT | |
|---|---|---|
| Last close | $255.48 | $112.47 |
| Market cap | $456.2B | $194.4B |
| P/E (FY) | 109.4× | 30.0× |
| P/S | 7.5× | 4.4× |
| Operating margin | 24.6% | 18.2% |
| Net margin | 6.9% | 14.7% |
| Return on equity | — | 13.1% |
| Sales growth (3y) | +1.8% | +0.5% |
| EPS growth (3y) | -29.1% | -1.6% |
| Dividend yield | 2.6% | 2.1% |
| 1-year return | +25.8% | -13.0% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| ABBV | ABT | |
|---|---|---|
| Institutional holders (13F) | 4,044 | 3,066 |
| Insider buyers − sellers (180d) | -2 | -3 |
| Congressional trades disclosed (180d) | 2 | 14 |
| Executive-branch officials on file — trades disclosed (180d) | 17 | 17 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
ABBV vs ABT: common questions
- Is ABBV bigger than ABT?
- ABBV carries the larger market cap — $456.2B against $194.4B, both struck on 2026-08-27.
- Which trades at a higher P/E, ABBV or ABT?
- ABBV, at a fiscal-year 109.4× against 30.0× for ABT. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have ABBV and ABT performed over the past year?
- ABBV returned +25.8% and ABT -13.0%, measured on the trailing calendar year to the last close.
- How many institutions hold ABBV and ABT?
- 4,044 13F filers report a position in ABBV and 3,066 in ABT, on the latest quarter in the panel.
- Are ABBV and ABT in the same industry?
- Both are filed with the SEC under Pharmaceutical Preparations, which is the classification this pairing is built on.
ABBV overview → · ABT overview → · ABBV institutional ownership → · ABT institutional ownership → · Congress and ABBV → · Congress and ABT → · Executive branch and ABBV → · Executive branch and ABT →
More in Pharmaceutical Preparations: ABBV vs ONC · ABBV vs REGN · ABBV vs TEVA · ABBV vs VRTX
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/abbv-vs-abt